Every 424B that Shattuck Labs, Inc. (STTK) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow STTK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full STTK filings page.
Shattuck Labs is offering 10,879,376 shares of common stock and pre-funded warrants to purchase 7,870,624 shares of common stock. The public offering price is $4.00 per share and the exercise price of each pre-funded warrant is $0.0001. Delivery is expected on or about June 11, 2026. Net proceeds to the company are estimated at approximately $70.5M before expenses (or approximately $81.1M if the underwriters’ 30-day option to purchase up to an additional 2,812,500 shares is exercised in full). The offering includes an underwriting syndicate and customary lock-ups; holders of pre-funded warrants will not have stockholder rights until exercise. The prospectus supplement also discloses recent clinical developments for lead candidate SL-325 and that warrant exercises and existing cash support a cash runway into 2029 based on management’s stated assumptions.
Shattuck Labs, Inc. files a preliminary prospectus supplement to offer shares of common stock and pre-funded warrants in a registered shelf offering, and disclosed recent clinical and financing developments.
The company announced Phase 1 data for lead antibody candidate SL-325 on June 8, 2026, reported notices to exercise approximately $54.9 million of common stock warrants (approximately 50.6M warrants), and stated existing cash, cash equivalents and short-term investments of $90.4 million as of March 31, 2026, with an expected funding runway into 2029 assuming full exercise of remaining warrants.
Shattuck Labs, Inc. is establishing an at-the-market stock offering program, registering shares of its common stock with an aggregate offering price of up to $75,000,000. The shares may be sold from time to time through Leerink Partners, which will act as sales agent on a commercially reasonable efforts basis and receive a commission of up to 3.0% of the gross sales price per share.
The company’s common stock trades on the Nasdaq Global Select Market under the symbol STTK, with a last reported sale price of $4.44 per share on January 21, 2026. Shattuck Labs is a biotechnology company developing treatments for inflammatory and immune‑mediated diseases, including its lead antibody program SL‑325. Net proceeds from any sales under this program are expected to fund ongoing and planned clinical trials, advancement of additional product candidates, and general corporate and working capital needs, but the company is not obligated to sell any specific amount.